Elite Plans Opioid NDA Submission After Phase III Success
This article was originally published in Scrip
Executive Summary
Elite Pharmaceuticals plans to submit a new drug application (NDA) to the US FDA by the end of this year based on positive Phase III results in the treatment of moderate to severe pain for ELI-200, an opioid-based pill designed with the company's proprietary abuse-deterrent technology (ART).